Search results - 5 results
Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study
chronic disease (OR a 0.22 (95% CI 0.08–0.62)), having received an mRNA-type vaccine (OR a 5.38 (95% CI 1.72–16.80)), and having received an influenza vaccine in 2020–2021 (OR a 3.79 (95% CI 1.30–11.07)). ...
The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff- study protocol description and presentation of preliminary findings on symptoms.
The presence of co-morbidities and immune ageing in the elderly lead to an increased susceptibility to COVID-19, as is the case for other influenza-like illnesses (ILI) or acute respiratory tract ...
Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015-20: a surveillance study.
from the national influenza surveillance networks in Belgium during the winter seasons of 2015-20. Respiratory specimens were collected through the severe acute respiratory infection (SARI) and the ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown. METHODS: DAW ...
All-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century.
century including those of the Spanish influenza pandemic. METHODS: Excess mortality predictions and COVID-19 mortality data were analysed for the period March 10th to June 21st 2020. The number of COVID-19 ...